KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBITDA (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBITDA for 13 consecutive years, with $211.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 373.07% to $211.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$27.0 million, a 88.97% increase, with the full-year FY2025 number at -$51.7 million, up 81.48% from a year prior.
  • EBITDA was $211.6 million for Q4 2025 at Xenon Pharmaceuticals, up from -$90.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $211.6 million in Q4 2025 to a low of -$90.5 million in Q3 2025.
  • A 5-year average of -$30.4 million and a median of -$44.3 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 3382.66% in 2021, then surged 373.07% in 2025.
  • Xenon Pharmaceuticals' EBITDA stood at $32.9 million in 2021, then tumbled by 213.96% to -$37.4 million in 2022, then plummeted by 43.42% to -$53.7 million in 2023, then tumbled by 44.29% to -$77.5 million in 2024, then soared by 373.07% to $211.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBITDA are $211.6 million (Q4 2025), -$90.5 million (Q3 2025), and -$83.8 million (Q2 2025).